Discovery of a potent tyrosine kinase AXL inhibitor bearing the 3-((2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino)pyrazine core

[Display omitted] •AXL has been a promising therapeutic target for cancers.•A side-chain ring closure medicinal chemistry approach was conducted.•15c bearing the 3-((2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino)pyrazine core was found to be most potent.•15c exhibited high anti-proliferative activ...

Full description

Saved in:
Bibliographic Details
Published inBioorganic & medicinal chemistry letters Vol. 29; no. 6; pp. 836 - 838
Main Authors Wang, Yueliang, Xing, Li, Ji, Yinchun, Ye, Jiqing, Dai, Yang, Gu, Wangting, Ai, Jing, Song, Zilan
Format Journal Article
LanguageEnglish
Published OXFORD Elsevier Ltd 15.03.2019
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:[Display omitted] •AXL has been a promising therapeutic target for cancers.•A side-chain ring closure medicinal chemistry approach was conducted.•15c bearing the 3-((2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino)pyrazine core was found to be most potent.•15c exhibited high anti-proliferative activity with IC50 values of 0.3 nM.•15c showed acceptable PK properties with the oral bioavailability of 24.8%. Starting from the recently launched FLT3/AXL multi-targeted inhibitor Gilteritinib (5), we conducted a side-chain ring closure medicinal chemistry approach leading to the identification of compound 15c as a highly potent AXL inhibitor in the biochemical and cellular anti-proliferative assays, with IC50 values of 1.2 and 0.3 nM, respectively. Compared with the reference compound 5, our new discovered AXL inhibitor 15c is more potent in both assays.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2019.01.018